Public deck

Arbutus (ABUS): the $179M settlement windfall hiding inside a pre-commercial HBV biotech

ABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.